Navidea to Present at Upcoming Investor Conference
DUBLIN, Ohio--(BUSINESS WIRE)-- Navidea Biopharmaceuticals, Inc. (NYSE MKT:NAVB) today announced that management will present at an upcoming investor conference. An audio webcast of the presentation will be available live at the URL links noted below. An archived version of the webcast will be available approximately two hours following the presentations and can be accessed within the Investors' section of the Navidea website http://ir.navidea.com.
2017 Biotech Showcase Conference in San Francisco on Monday, January 9, 2017 at 4:30 p.m., Pacific Time (7:30 p.m. ET). Webcast Link: https://event.webcasts.com/starthere.jsp?ei=1131242
Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) is a biopharmaceutical company focused on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. Navidea is developing multiple precision-targeted products and platforms including Manocept™ and NAV4694 to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek® (technetium Tc 99m tilmanocept) injection, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. The development activities of the Manocept immunotherapeutic platform will be conducted by Navidea in conjunction with its subsidiary, Macrophage Therapeutics. Navidea’s strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts. For more information, please visit www.navidea.com.
Investors & Media
Jed Latkin, 614-973-7490
COO & CFO
Source: Navidea Biopharmaceuticals, Inc.
Released January 6, 2017